Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia

• Published in: Journal of clinical oncology Vol. 25; no. 1; pp. 25 - 31
• Main Authors: Giles, Francis, Rizzieri, David, Karp, Judith, Vey, Norbert, Ravandi, Farhad, Faderl, Stefan, Khan, Khuda Dad, Verhoef, Gregor, Wijermans, Pierre, Advani, Anjali, Roboz, Gail, Kantarjian, Hagop, Bilgrami, Syed Fazl Ali, Ferrant, Augustin, Daenen, Simon M G J, Karsten, Verena, Cahill, Ann, Albitar, Maher, Mufti, Ghulam, O'Brien, Susan
• Format: Journal Article
• Language: English
• Published: Baltimore, MD American Society of Clinical Oncology 01.01.2007; Lippincott Williams & Wilkins
• Subjects: Aged; Aged, 80 and over; Antineoplastic agents; Antineoplastic Agents, Alkylating - adverse effects; Antineoplastic Agents, Alkylating - therapeutic use; Biological and medical sciences; Chemotherapy; Female; Humans; Hydrazines - adverse effects; Hydrazines - therapeutic use; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - mortality; Male; Medical sciences; Middle Aged; Models, Chemical; Pharmacology. Drug treatments; Prognosis; Remission Induction; Risk; Sulfonamides - adverse effects; Sulfonamides - therapeutic use; Time Factors; Treatment Outcome; Tumors; Human; Antineoplastic agent; Alkylating agent; Chemotherapy; Cancerology; Treatment; Phase II trial; Adult; Malignant hemopathy; Hydrazine; Elderly; Acute myelocytic leukemia

Cloretazine (VNP40101M) is a sulfonylhydrazine alkylating agent with significant antileukemia activity. A multicenter phase II study of cloretazine was conducted in patients 60 years of age or older with previously untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). C...